Skip to main content

Advertisement

SpringerLink
Log in

The effect of variable cigarette consumption on the interaction with clozapine and olanzapine

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

Cigarette smoking has been shown in several studies to induce the metabolism of the cytochrome P4501A2 (CYP1A2) substrates clozapine and olanzapine. The aim of the present study was to investigate the dose-dependent effect of cigarette smoking on serum concentrations of these drugs in a naturalistic setting.

Methods

In 73 schizophrenic patients recruited from psychiatric nursing homes, patient characteristics, smoking habits, drug dosing and serum concentrations of clozapine (n=33) and olanzapine (n=40) were registered. Concentration to dose (C/D) ratios of clozapine and olanzapine in non-smokers and subgroups of smokers were compared.

Results

Fifty-nine patients (80%) were smokers and these were stratified into the following groups according to smoking habits: 1–6 (n=0), 7–12 (n=13), 13–19 (n=18) and ≥20 (n=28) cigarettes daily. While the mean ratio was twice as high in non-smokers compared to smokers for both drugs (p<0.01), the C/D ratios of clozapine and olanzapine were not significantly different between the subgroups of smokers (p >0.15). Absolute serum concentrations were also higher in non-smokers compared to smokers: 50% for clozapine (p=0.058) and 67% for olanzapine (p<0.01).

Conclusion

A daily consumption of 7–12 cigarettes is probably sufficient for maximum induction of clozapine and olanzapine metabolism. A 50% lower starting dose of both drugs in non-smokers seems rational to avoid side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Aleman A, Kahn RS, Selten JP (2003) Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 60:565–571

    Article  PubMed  Google Scholar 

  2. Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML et al (2004) Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 26:167–170

    Article  PubMed  CAS  Google Scholar 

  3. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P et al (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped Patients. Ther Drug Monit 27:539–543

    Article  PubMed  CAS  Google Scholar 

  4. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177–193

    Article  PubMed  CAS  Google Scholar 

  5. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S et al (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23:119–127

    Article  PubMed  CAS  Google Scholar 

  6. de LJ, Diaz FJ (2005) A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76:135–157

    Article  Google Scholar 

  7. Gex-Fabry M, Balant-Gorgia AE, Balant LP (2003) Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25:46–53

    Article  PubMed  CAS  Google Scholar 

  8. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796

    PubMed  CAS  Google Scholar 

  9. Khan AY, Preskorn SH (2005) Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 11:289–301

    Article  PubMed  Google Scholar 

  10. Lohr JB, Flynn K (1992) Smoking and schizophrenia. Schizophr Res 8:93–102

    Article  PubMed  CAS  Google Scholar 

  11. Meyer JM (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 21:569–574

    Article  PubMed  CAS  Google Scholar 

  12. Olesen OV, Linnet K (2001) Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 41:823–832

    Article  PubMed  CAS  Google Scholar 

  13. Perry PJ, Argo TR, Carnahan RM, Lund BC, Holman TL et al (2005) The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 25:250–254

    Article  PubMed  CAS  Google Scholar 

  14. Perry PJ, Bever KA, Arndt S, Combs MD (1998) Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44:733–738

    Article  PubMed  CAS  Google Scholar 

  15. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S et al (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55(Suppl B):133–136

    PubMed  Google Scholar 

  16. Raaska K, Raitasuo V, Laitila J, Neuvonen PJ (2004) Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 94:13–18

    Article  PubMed  CAS  Google Scholar 

  17. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT et al (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24:70–78

    Article  PubMed  CAS  Google Scholar 

  18. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445–449

    Article  PubMed  CAS  Google Scholar 

  19. Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT (1999) Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 85:244–246

    Article  PubMed  CAS  Google Scholar 

  20. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F (2002) Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24:518–526

    Article  PubMed  CAS  Google Scholar 

  21. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN et al (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162:1281–1290

    Article  PubMed  Google Scholar 

  22. Tyson PJ, Roberts KH, Mortimer AM (2004) Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 114:593–611

    Article  PubMed  CAS  Google Scholar 

  23. Van der Weide J, Steijns LS, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13:169–172

    Article  PubMed  Google Scholar 

  24. Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W (2005) Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 25:570–574

    Article  PubMed  CAS  Google Scholar 

  25. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 17:141–143

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychopharmacology, Diakonhjemmet Hospital, Postbox 85, Vinderen, Oslo, 0319, Norway

    Tore Haslemo, Lars Tanum, Espen Molden & Helge Refsum

  2. Department of Psychiatry, Lovisenberg Hospital, Oslo, Norway

    Per Haakon Eikeseth

Authors
  1. Tore Haslemo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Per Haakon Eikeseth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars Tanum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Espen Molden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Helge Refsum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tore Haslemo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haslemo, T., Eikeseth, P.H., Tanum, L. et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 62, 1049–1053 (2006). https://doi.org/10.1007/s00228-006-0209-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-006-0209-9

Keywords

Search

Navigation